However, some secondary measures of nerve impairment did improve, especially in participants with higher cardiovascular risk and moderate BMI.7 Shorter-term trials have shown that 600mg/day of oral racemic ALA reduced neuropathy symptoms like burning, tingling, and numbness in as little as 35 weeks.4 20 A 2010 meta-analysis concluded that oral ALA can improve symptoms of diabetic neuropathy, but noted variability in effect sizes across trials and better results with intravenous administration.1 Despite promising results from some trials, a recent systematic review evaluating eight randomized controlled trials indicates that findings on ALA's effectiveness in treating diabetic neuropathy symptoms are inconsistent.23 While ALA proved safe and tolerable across these studies, the review concluded that definitive evidence supporting significant benefits is limited
Stimularea angiogenezei sprijin mbuntirea circulaiei sanguine n zonele afectate
The Patient: 32-year-old, 16 weeks pregnant, with pre-existing Type 2 diabetes managed on insulin
Further, mitophagy was proposed as a specific therapeutic target to advance treatments of ischemic stroke [540]
Weeks 19 through 24: 12mg weekly (maintenance begins) The final step to full maintenance dose
Redox-based regulation of signal transduction: Principles, pitfalls, and promises
